इसराइल - हिब्रू - Ministry of Health

ג'י אי מדיקל סיסטמס ישראל - צוות טכני - the ge lightspeed ct 750 hd ct x-ray system is intended to produce cross-sectional images of the body .

इसराइल - हिब्रू - Ministry of Health

a.l. medi-market ltd. - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 50 mcg / 1 ml - palonosetron

इसराइल - हिब्रू - Ministry of Health

a.l. medi-market ltd. - zoledronic acid as monohydrate - תרכיז להכנת תמיסה לאינפוזיה - zoledronic acid as monohydrate 0.8 mg / 1 ml - zoledronic acid

इसराइल - हिब्रू - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

इसराइल - हिब्रू - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

इसराइल - हिब्रू - Ministry of Health

אינטרביוטי קוסמטיקס ישראל בעמ - הגנה מקרני שמש

इसराइल - हिब्रू - Ministry of Health

אינטרביוטי קוסמטיקס ישראל בעמ - אנטיפרספירנט

इसराइल - हिब्रू - Ministry of Health

abic veterinary products ltd - enrofloxacin - תמיסה - enrofloxacin 100 mg/ml

इसराइल - हिब्रू - Ministry of Health

intervet ( israel) ltd - dihydrostreptomycin as sulfate; nafcillin as sodium; procaine benzylpenicillin - משחה - procaine benzylpenicillin 300 mg / 3 g; dihydrostreptomycin as sulfate 100 mg / 3 g; nafcillin as sodium 100 mg / 3 g

इसराइल - हिब्रू - Ministry of Health

intervet ( israel) ltd - dihydrostreptomycin sulfate; nafcillin as nafcillin sodium; procaine benzylpenicillin - משחה - procaine benzylpenicillin 300 mg / 3 g; dihydrostreptomycin sulfate 100 mg / 3 g; nafcillin as nafcillin sodium 100 mg / 3 g